Share on StockTwits

OncoGenex Pharmaceuticals (NASDAQ:OGXI) CMO Cindy Jacobs sold 5,650 shares of the company’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $3.17, for a total transaction of $17,910.50. Following the sale, the chief marketing officer now directly owns 43,255 shares in the company, valued at approximately $137,118. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of OncoGenex Pharmaceuticals (NASDAQ:OGXI) traded down 3.64% during mid-day trading on Monday, hitting $3.18. The stock had a trading volume of 30,242 shares. OncoGenex Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $14.25. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $6.97. The company’s market cap is $67.2 million. OncoGenex Pharmaceuticals also was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 305,595 shares, a decrease of 45.7% from the July 15th total of 562,692 shares. Based on an average daily volume of 113,186 shares, the short-interest ratio is presently 2.7 days. Currently, 1.6% of the company’s shares are sold short.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) last announced its earnings results on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.08. Analysts expect that OncoGenex Pharmaceuticals will post $-1.75 EPS for the current fiscal year.

OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.

Receive News & Ratings for OncoGenex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.